Skip to main content

Table 4 OARSI responder criteria

From: Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis

Number (%) of Responders 0.03 mg
(N = 7)
0.1 mg
(N = 6)
0.3 mg
(N = 6)
1 mg
(N = 6)
All
(N = 25)
Placebo
(N = 8)
Week 4 3 (42.9%) 4 (66.7%) 1 (16.7%) 2 (33.3%) 10 (40%) 1 (12.5%)
Week 8 3 (42.9%) 4 (66.7%) 2 (33.3%) 2 (33.3%) 11 (44%) 0 (0%)
Week 12 1 (14.3%) 4 (66.7%) 2 (33.3%) 1 (16.7%) 8 (32%) 1 (12.5%)
Week 24 1 (14.3%) 5 (83.3%) 2 (33.3%) 1 (20%) 9 (37.5%) 1 (12.5%)